Premium
When Nalanda Capital bet on Thyrocare Technologies Ltd in March, the private equity-style investor in public equities was likely enticed by the boost the diagnostics industry was expected to get because of the coronavirus pandemic. Seven months down the line the jury is still out on whether the industry is ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
